All Stories

  1. Wearable Devices and Machine Learning in Cardiovascular Monitoring: Current Evidence and Future Directions for Precision Medicine
  2. First-line maintenance therapy patterns in BRCA wild-type and HRD-negative advanced epithelial ovarian cancer: A European real-world study.
  3. Molecular fingerprints of drug-resistant epilepsy identified through liquid biopsy profiling
  4. On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials
  5. Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib
  6. The Current Landscape of Artificial Intelligence in Positron Emission Tomography (PET) Imaging Across the Cancer Continuum
  7. Genetically Optimized Modular Neural Networks for Precision Lung Cancer Diagnosis: Exploratory Study of Novel Approach
  8. Coronavirus disease 2019-associated mucormycosis and cytomegalovirus infection: a case report
  9. A multi-modal approach for decision making in bladder cancer
  10. Unlocking precision: Bispecific T cell engagers and the next frontier in uro-oncology
  11. Idiopathic Inflammatory Myopathy With Normal Creatine Kinase Levels in an Elderly Patient: A Diagnostic Challenge
  12. Redefining Chemotherapy-Related Headaches: From Pathobiology to Differential Diagnosis and Management
  13. From Crisis to Cancer: Diabetic Ketoacidosis Unmasking a Malignancy of Unknown Origin
  14. Cancer Reversion Therapy: Prospects, Progress and Future Directions
  15. Efficacy of ketogenic metabolic therapy as an adjuvant to the current standard of care in the treatment of glioblastoma: A systematic review of clinical trials
  16. Molecular engines driving biogenesis, trafficking and release of exosomes: SNARE proteins
  17. The risk of lung cancer from vaping or e-cigarette usage: a systematic review
  18. Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review
  19. Resolution of Persistent Fever and Systemic Inflammation in a Metastatic Gastrointestinal Stromal Tumour (GIST) With Imatinib
  20. Advancing circular economy practices in radiography: a narrative review of sustainable medical imaging
  21. Therapeutic opportunities in EBV-positive gastric cancer subtypes
  22. SKP2 at the crossroads of proliferation and immune evasion: a new target in the tumor microenvironment
  23. Smart Nanomedicines for Neurodegenerative Diseases: Empowering New Therapies with Molecular Imaging and Artificial Intelligence
  24. Enhancing home rehabilitation through AI-driven virtual assistants: a narrative review
  25. Generative artificial intelligence in predictive analysis of diabetes and its complications: a narrative review
  26. Smart emergency care: a narrative review of predictive machine learning models
  27. Comparative Analysis of Large Language Models in Dermatological Diagnosis: An Evaluation of Diagnostic Accuracy
  28. The evolution of targeted intra operative radiotherapy in early breast cancer
  29. The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation
  30. Agnostic Biomarkers and Molecular Signatures in Colorectal Cancer—Guiding Chemotherapy and Predicting Response
  31. Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy
  32. Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
  33. Enhancing Parkinson’s disease prediction using meta-heuristic optimized machine learning models
  34. Evaluating AI adoption in healthcare: Insights from the information governance professionals in the United Kingdom
  35. The Impact of AI-Driven Chatbot Assistance on Protocol Development and Clinical Research Engagement: An Implementation Report
  36. Stacked Ensemble Learning for Classification of Parkinson’s Disease Using Telemonitoring Vocal Features
  37. Urban Microclimates and Their Relationship with Social Isolation: A Review
  38. Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis
  39. Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review
  40. Reversing Epigenetic Dysregulation in Neurodegenerative Diseases: Mechanistic and Therapeutic Considerations
  41. Disentangling the Gordian Knot of parasympathetic innervations in arthritic joint
  42. AI-Driven Advancements in Orthodontics for Precision and Patient Outcomes
  43. The current landscape of artificial intelligence in computational histopathology for cancer diagnosis
  44. Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
  45. Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment
  46. AI-Driven Advances in Low-Dose Imaging and Enhancement—A Review
  47. Spinal MRI in Patients with Suspected Metastatic Spinal Cord Compression: A Quality Improvement Audit in a District General Hospital in Kent, UK
  48. Diagnosis and Treatment of Gestational Non-Epithelial Ovarian Cancer: A Systematic Review
  49. Male Breast Cancer: A Single Institutional Clinicopathological Profiling
  50. Enhancing Ophthalmic Diagnosis and Treatment with Artificial Intelligence
  51. Precision oncology through next generation sequencing in hepatocellular carcinoma
  52. Spotlight on Lung Cancer Disparities in India
  53. Molecular biomarkers of glial activation and injury in epilepsy
  54. Integrating AI into Cancer Immunotherapy—A Narrative Review of Current Applications and Future Directions
  55. Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
  56. Molecular Biology of Cancer—Interplay of Malignant Cells with Emerging Therapies
  57. Construction of a prognostic survival model with tumor immune-related genes for breast cancer
  58. An overview of immune checkpoint inhibitor toxicities in bladder cancer
  59. An orthogonal approach for analysis of underivatized steroid hormones using ultrahigh performance supercritical fluid chromatography-mass spectrometry (UHPSFC-MS)
  60. AI-Guided Cancer Therapy for Patients with Coexisting Migraines
  61. Artificial Intelligence – Guided Cancer Therapy for Patients with Migraine Comorbidities
  62. Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer
  63. Paediatric Anatomical Models in Radiotherapy Applications
  64. Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape
  65. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
  66. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
  67. lncRNA Biomarkers of Glioblastoma Multiforme
  68. Large Language Models in Oncology: Revolution or Cause for Concern?
  69. The Application of Radiomics and AI to Molecular Imaging for Prostate Cancer
  70. A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer
  71. A rare case of metaplastic breast carcinoma from India: Towards precision oncology
  72. Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma – A Meta-analysis
  73. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4
  74. Exosomes in Renal Cell Cancer: Diagnostic and Therapeutic Nanovehicles
  75. Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum
  76. Medical oncology: challenges in 2022
  77. Frontiers of Molecular Biology of Cancer
  78. Immune checkpoint inhibitors in patients with cancers of unknown primary
  79. Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness
  80. Frontiers of Ovarian Carcinosarcoma
  81. COVID-19 Associated Mucormycosis and Cytomegalovirus Infection – A Case Report
  82. Renal Cell Cancer – Insights in Drug Resistance Mechanisms
  83. The integration of palliative care with oncology: the path ahead
  84. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine
  85. Exosomes in the Diagnosis and Treatment of Renal Cell Cancer
  86. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study
  87. Gestational Renal Cell Cancer – An Update
  88. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
  89. Re: Pain and Health-related Quality of Life with Olaparib Versus Physician’s Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An O...
  90. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer – a Retrospective UK Single-Center Study
  91. Emerging Hallmarks of the Tumour Microenvironment of Gliomas and the Interplay with Immunotherapy
  92. Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors
  93. Advances in adoptive T-cell therapy for metastatic melanoma
  94. Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
  95. Impact of COVID-19 on cancer services and patients’ outcomes: a retrospective single-center study
  96. State-of-the-Art Molecular Oncology in UK
  97. Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy
  98. Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre
  99. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
  100. Prostate cancer—what about oligometastatic disease and stereotactic ablative radiotherapy?—a narrative review
  101. From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary
  102. Constrictive Pericarditis–A Cloak Camouflaging Lymphoma
  103. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
  104. Aberrations of DNA Repair Pathways in Prostate Cancer—The State of the Art
  105. HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK
  106. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
  107. Efficacy and Safety of COVID-19 Vaccines—An Update
  108. A Primary Mediastinal Monophasic Spindle-Cell Synovial Sarcoma with Superior Venacaval Obstruction
  109. Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
  110. Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes
  111. Chromosomal instability in cancers of unknown primary
  112. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
  113. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
  114. COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
  115. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
  116. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls
  117. Sarcoma of unknown primary: myth or reality?
  118. Systematic review of the CUP trials characteristics and perspectives for next-generation studies
  119. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
  120. Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer
  121. Epilepsy and Diagnostic Dilemmas: The Role of Language and Speech-Related Seizures
  122. Metastatic Anorectal Melanoma Presenting as Seizures: An Infrequent Culprit
  123. Case of cerebral venous thrombosis on a patient with background of nephrotic syndrome
  124. Systematic review of fetal and placental metastases among pregnant patients with cancer
  125. Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
  126. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
  127. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
  128. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
  129. The Experience of a Single NHS England Trust on the Impact of the COVID-19 Pandemic on Junior and Middle-Grade Doctors: What Is Next?
  130. Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
  131. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
  132. Unraveling the Wide Spectrum of Melanoma Biomarkers
  133. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary
  134. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology
  135. Cancer-Associated Thrombosis: A New Light on an Old Story
  136. Comparative genomic characterization of melanoma of known and unknown primary
  137. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities
  138. Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK
  139. Melanoma of unknown primary: New perspectives for an old story
  140. Current and future immunotherapy approaches in ovarian cancer
  141. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
  142. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review
  143. Metformin and ovarian cancer: the evidence
  144. NOTCH signalling in ovarian cancer angiogenesis
  145. Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered
  146. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
  147. Ovarian cancer: state of the art and perspectives of clinical research
  148. Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches
  149. Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence
  150. An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
  151. Wise Management of Ovarian Cancer: On the Cutting Edge
  152. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
  153. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
  154. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
  155. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
  156. PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
  157. The Developing Story of Predictive Biomarkers in Colorectal Cancer
  158. Ovarian carcinosarcoma: Current developments and future perspectives
  159. Management of Recurrent Uterine Cervical Cancer
  160. Spinal Ewing Sarcoma Debuting with Cord Compression: Have We Discovered the Thread of Ariadne?
  161. Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges
  162. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives
  163. Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature
  164. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives
  165. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects
  166. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
  167. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer
  168. Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
  169. Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review
  170. Current and future biomarkers in colorectal cancer
  171. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
  172. Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies
  173. Cancer specific risk in multiple sclerosis patients
  174. Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence
  175. Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor
  176. Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis
  177. Lung cancer in pregnancy: Report of nine cases from an international collaborative study
  178. Renal cell carcinoma in pregnancy: a rare coexistence